Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA appropriations bill passes House

This article was originally published in The Tan Sheet

Executive Summary

The House on Aug. 2 passed its appropriations bill, H.R. 3161, that includes FDA funding, which proposes $1.69 bil. in direct funding for the agency. No significant changes affecting FDA were made from the bill sent top the floor by the Agriculture Appropriations Subcommittee (1"The Tan Sheet" July 23, 2007, p. 4). The same day, Sen. Mike Enzi, R-Wyo., asked Majority Leader Harry Reid, D-Nev., to delay naming conferees for the legislation. "If we do this too early, we set ourselves up for the blame game, not for getting this key legislation done," Enzi said. The Senate has not yet passed its corresponding bill, S. 1859...

You may also be interested in...



Appropriators Boost FDA Budget For Food Safety While Opposing Lab Closings

House and Senate appropriators make it known in reports on FDA's fiscal 2008 appropriation that they question the agency's plan to close more than half of its field labs, with the House bill specifically banning funding for the reorganization

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel